Clinically, FLT3-ITD mutated AML is associated with higher rates of relapse and inferior overall survival, although the full prognostic impact is affected both by mutant allele burden and presence of co-existing mutations (7). This evidence concerns the gene FLT3 and acute myeloid leukemia.